Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%

Program Discontinuation:
Shattuck Labs has discontinued its CD47 program (SL-172154) in acute myeloid leukemia and higher-risk myelodysplastic syndromes due to disappointing early results.

Workforce Reduction:
The company is laying off approximately 40% of its workforce as part of a restructuring plan to focus on its DR3 antagonist antibody, SL-325.

New Focus:
Shattuck Labs is now focusing on SL-325, a DR3 antagonist antibody, for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases.

Clinical Development:
The company plans to initiate clinical development of SL-325 in IBD patients, with an Investigational New Drug (IND) application expected in the third quarter of 2025.

Financial Impact:
The restructuring is expected to extend the company’s financial resources into 2027, with a balance of $105.3 million in cash, cash equivalents, and investments as of June 30, 2024.

Termination of License Agreement:
Shattuck Labs and Ono Pharmaceutical Co., Ltd. have mutually agreed to terminate their collaboration and license agreement.